- Sunwoo Koo
- Research Assistant Professor
- Room 118 TVMDL
- Undergraduate Education
- B.S, in Biophysics, Iowa State, University
- Graduate Education
- Ph.D. in Biomedical Science, Texas A&M University
- KISTI Research Award, Survey of advanced technology in therapeutics peptides conjugation
- Texas A&M University HSC Competitive Research Award
Dr. Koo is a Research Assistant Professor in the Texas A&M Veterinary Medical Diagnostic Laboratory and the Department of Animal Science, College of Agriculture and Life Sciences at Texas A&M University. Dr. Koo received a B.S. in biophysics from Iowa State University. He obtained a Ph.D. in biomedical science from Texas A&M University.
After earning the doctoral degree, he pursued postdoctoral training in the Department of Biochemistry and Biophysics and worked as an Assistant Research Scientist in the Department of Neuroscience and Experimental Therapeutics at Texas A&M University.
Dr. Koo’s primary research focuses are the development of advanced diagnostics and therapeutics by the discovery of biomarkers, protein engineering, and genetic engineering. Development of Diagnostics: Precise and cost-effective diagnosis is important to control disease. He employs exosomes as biomarkers to develop diagnostic tools for the early stage of infectious diseases.
Further, he will investigate the role of exosomes in infectious communication between pathogens. Protein engineering is widely applied in the development of diagnostic methods. He will focus on enhancing the sensitivity of diagnostic methods through the use of engineered peptides and antibodies. In addition, he will employ NGS to develop techniques for the identification of unknown pathogens.
Cancer Therapeutics: He previously found that engineered pore-forming toxins lyse target cancer cells with two-fold specificity.
Based on this finding, he will develop personalized anticancer therapeutics including redirecting pore-forming toxin toward cancer cells, intracellular anticancer drug delivery through the pores formed on target cell membranes, and ‘toxin-tagging immunotherapeutics’ that will trigger the immune system to kill toxin-bound cancer cells.